Studies have shown that overexpression of YBX1 is associated with various tumor types’ resistance to therapy, cell proliferation, and prognosis, such as breast cancer, esophageal cancer, lung cancer, sarcomas, prostate cancer, glioblastoma, and non-Hodgkin lymphoma (32, 33). Here, YBX1 is linked to lung carcinoma.